Uveal Melanoma in the Iranian Population: Two Decades of Patient Management in a Tertiary Eye Center Publisher



Riaziesfahani H^{1, 2} ; Amini A³ ; Masoomian B¹ ; Yaseri M⁴ ; Sabour S⁵ ; Rashidinia A² ; Arjmand M¹ ; Rafizadeh SM⁶ ; Johari M⁷ ; Khalili Pour E² ; Ghassemi F^{1, 2} Show Affiliations
Source: International Journal of Retina and Vitreous Published:2024

Abstract

Background: To assess the characteristics and outcomes of uveal melanoma management at a tertiary center in the Middle East. Methods: A study on 164 patients with uveal melanoma was conducted by reviewing the available medical records, ultrasound, and pathology report results. Age at diagnosis, tumor location and size, treatment mode, visual outcome, metastasis, mortality, and survival were studied. Results: The mean age of patients was 52.0 ± 15.0 years, and 52.5% were male. Choroidal melanoma was the most common uveal melanoma, followed by the ciliary body and iris melanoma. The mean thickness of tumors was 8.29 ± 3.29. The majority of patients (n = 111, 67.9%) were managed by brachytherapy with ruthenium-106 plaques. Enucleation was performed primarily in 46 (28%) patients and secondarily in nine (5.5%) patients. The sexual disparity was detected as the proximity of uveal melanoma to the fovea in males. For a 61-month mean follow-up period, mortality occurred in eight of our cases, six of which were due to metastasis. The most common site for distance metastasis was the liver (5/6), followed by the lung (1/6). The five-year and eight-year overall survival (OS) rate was 0.947%± 0.019. The 5-year survival rate reached zero in metastatic patients. OS was not statistically different depending on the age, tumor diameters, the primary treatment received, or the histopathologic findings (p > 0.50 for all). Conclusion: In this study, individuals diagnosed with UM exhibited an OS rate of around 94% at the five-year mark, which remained consistent up to eight years. Notably, the presence of distance metastasis emerged as the sole statistically significant factor influencing overall survival. © The Author(s) 2024.